Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 18, Number 1—January 2012

Research

Invasive Meningococcal Capsular Group Y Disease, England and Wales, 2007–2009

Shamez N. LadhaniComments to Author , Jay Lucidarme, Lynne S. Newbold, Stephen J. Gray, Anthony D. Carr, Jamie Findlow, Mary E. Ramsay, Edward B. Kaczmarski, and Raymond Borrow
Author affiliations: Health Protection Agency, London, UK (S.N. Ladhani, M.E. Ramsay); Health Protection Agency, Manchester, UK (J. Lucidarme, L.S. Newbold, S.J. Gray, A.D. Carr, J. Findlow, E.B. Kaczmarski, R. Borrow); University of Manchester, Manchester (R. Borrow)

Main Article

Table 2

Clinical presentation of, risk factors for, and outcome of patients with invasive meningococcal capsular group Y disease, England and Wales, 2007–2009

Variable Age group, y, no. (%) patients
Total, n = 65
<25, n = 20 25–64, n = 19 65–84, n = 13 >85, n = 13
Female sex 11 (55) 14 (74) 10 (77) 12 (92) 47 (72)
Travel* 2 (10) 2 (11) 1 (8) 0 5 (8)
Clinical feature
Meningitis 8 (40) 11 (58) 2 (15) 1 (8) 23 (35)
Pneumonia 1 (5) 3 (16) 5 (39) 10 (77) 19 (29)
Septicemia 10 (50) 2 (11) 4 (31) 1 (8) 17 (26)
Other 1 (5) 3 (16) 2 (15) 1 (8) 7 (11)
Underlying conditions† 3 (15) 5 (26) 7 (54) 10 (77) 25 (39)
Immune deficiency‡ 2 (10) 1 (5) 2 (15) 3 (23) 8 (12)
Sequelae§ 1 (5) 1 (5) 0 1 (8) 3 (5)
Deaths 2 (10) 1 (5) 2 (15) 7 (54) 12 (19)

*Travel-associated infection included 2 visitors from Australia and South America and 3 residents who had traveled to Jamaica and Thailand and taken a Mediterranean cruise in the preceding 4 weeks.
†Underlying medical conditions included complement deficiency (1 person), diabetes mellitus (1), and systemic lupus erythematosus among persons <25 years of age; chronic liver disease (3), diabetes mellitus (1), and rheumatoid arthritis on immunosuppressive therapy (1) among persons 25–64 years of age; malignancy undergoing chemotherapy (2), diabetes mellitus (2), chronic heart disease (2), and chronic respiratory disease (1) among persons 65–84 years of age; and chronic heart disease (7), malignancy undergoing chemotherapy (2), chronic respiratory disease (1), and rheumatoid arthritis on immunosuppressive therapy (1) among persons >85 years of age.
‡Immunodeficiency included malignancy receiving chemotherapy (4 persons), autoimmune disease requiring immunosuppressant therapy (3), and complement deficiency (1).
§Sequelae included hemiparesis after meningitis in a toddler, bilateral sensorineural deafness requiring cochlear implantat after meningitis in an adult, and chronic renal insufficiency in an elderly person with septicemia.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO